Merck & Co., Inc.
Close on Nov 20, 2026Market cap $329.91BP/E 107.0Yield 2.45%
Merck Finite-Lived Intangible Assets by Year
Finite-Lived Intangible Assets — Products & Developed Technology, Net ($M) ($M)
Merck Finite-Lived Intangible Assets: $21,328M in FY2025, up 95.3% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 8 Goodwill and Other Intangibles.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-Lived Intangible Assets — Products & Developed Technology, Net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21,328 | +95.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 10,922 | +85.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 5,878 | -13.7% | Form 10-K (filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 6,810 | – | Form 10-K (filed 2024-02-26) ↗ |
Breakdown
What makes up finite-Lived Intangible Assets
- Products & Developed Technology Intangibles — Gross Carrying Amount ($M)42,038 · FY2025
- Products & Developed Technology Intangibles — Accumulated Amortization ($M)20,710 · FY2025
- Indefinite-Lived Intangible Assets — In-Process R&D (IPR&D) Carrying Value ($M)427 · FY2025
- Intangible Asset Amortization Expense ($M)2,800 · FY2025
- Goodwill — Pharmaceutical Segment ($M)17,905 · FY2025
- Product Intangible Asset Carrying Value — Winrevair (sotatercept — Acceleron acquisition) ($M)5,400 · FY2025
- Product Intangible Asset Carrying Value — Adempas (riociguat) ($M)280 · FY2025
Cite this data
StockData. (2026). Merck Finite-Lived Intangible Assets ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/intang-dev-tech-net
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?